Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of IFN (about 5 IU to about 2500 IU of IFN-alpha) to a patient in need thereof. In one embodiment the IFN is alpha IFN or beta IFN, and more particularly, in one embodiment the administered biologically active IFN is human alpha IFN.

Abstract: Disclosed herein is related to an operating method, and a memory module with wireless communication component. An exemplary example of the invention describes the memory module providing a control unit which coupled to both a wireless communication component such as an NFC chip, and anon-volatile memory unit. The memory module exemplarily uses an eMMC bus to interconnect a cellular phone system and the control unit. It is advantaged that when any data required to be transmitted between the NFC chip and the cellular phone system, a partition is specified to the chip according a partition table for further access task.

Abstract: Disclosed herein is related to an operating method, and a memory module with wireless communication component. An exemplary example of the invention describes the memory module providing a control unit which coupled to both a wireless communication component such as an NFC chip, and anon-volatile memory unit. The memory module exemplarily uses an eMMC bus to interconnect a cellular phone system and the control unit. It is advantaged that when any data required to be transmitted between the NFC chip and the cellular phone system, a partition is specified to the chip according a partition table for further access task.

Abstract: A composition of human interferon-alpha (IFN-?) subtypes produced from human lymphoblastoid cells is disclosed. These purified IFN-? composition comprise higher specific activities and may be applied in the treatment of cancers, viruses, and immuno diseases.

Abstract: The present invention provides a process for preparing a mixture of amino-containing phosphazenes having the following general formula (I) by reacting a (NPCl2)n phosphazene mixture with NH3 and HOR in the presence of a tertiary amine catalyst: NnPn(NH2)x(OR)2n−x  (l) wherein n≧3, 1≦x<2n, and R is phenyl or C3-C6 alkyl. In addition to simultaneously carrying out amination and esterification, the process of the present invention also simultaneously performs a regeneration of the catalyst. Furthermore, the invented process is a water-free process without the problem of a large quantity of waste water. Ammonium chloride, a by-product of the invented process, can be recovered in a subsequent process.